Analysts Name Top Biotech Stocks for 2010: BioBuzz
Either way, the search for a new Biogen CEO, which the company said is already underway, will be an interesting process to watch. Now that Mullen is essentially a lame duck, it's reasonable to expect the company's board -- including Icahn's proxies -- to take a more active management role.
Naturally, speculation will increase that Biogen could be placed back on the sale block.
It might be lost amidst all the palace intrigue, but Mullen did manage to bring home a 12% return for shareholders in 2009 -- making Biogen the only big-cap biotech stock to close the year in the green.
Still, Biogen does face challenges ahead with the increase in the number of cases of the serious brain infection known as PML tied to use of its multiple sclerosis drug Tysabri. The company has also experienced setbacks recently with its late-stage drug pipeline.Biogen shares closed Monday at $53.64, ahead of the announcement of Mullen's retirement.
Help Wanted: Big-Cap Biotech CEORunning a multi-billion dollar, profitable biotech firm isn't a position that comes available very often, which makes the search for a new CEO at Biogen Idec a relatively rare event. Mullen joined Biogen in 1989 and rose to the CEO post in 2000, the same year that Amgen's (AMGN) current CEO Kevin Sharer also took over the top job at his company. Genzyme's (GENZ) CEO Henri Termeer is the longest-serving CEO in the big-cap biotech group, named to the position in 1985. (How long he stays there is also an intriguing question for 2010.) John Martin became Gilead Sciences (GILD) CEO in 1996, while Celgene (CELG) CEO Sol Barer is a relative newcomer, having been promoted to his position in 2006. (Although Barer's tenure with Celgene began in 1987.)
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV